Cart
sales@molnova.com
TN-16
CAS No. 33016-12-5
TN-16( —— )
Catalog No. M21073 CAS No. 33016-12-5
TN-16 is a microtubule polymerization inhibitor?(IC50 :0.4-1.7 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 177 | Get Quote |
|
| 5MG | 268 | Get Quote |
|
| 10MG | 408 | Get Quote |
|
| 25MG | 672 | Get Quote |
|
| 50MG | 945 | Get Quote |
|
| 100MG | 1278 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTN-16
-
NoteResearch use only, not for human use.
-
Brief DescriptionTN-16 is a microtubule polymerization inhibitor?(IC50 :0.4-1.7 μM).
-
DescriptionTN-16 is a microtubule polymerization inhibitor?(IC50 :0.4-1.7 μM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptormicrotubule polymerization
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number33016-12-5
-
Formula Weight306.36
-
Molecular FormulaC19H18N2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(Nc1ccccc1)=C1C(=O)NC(Cc2ccccc2)C1=O
-
Chemical Name3-[1-(Phenylamino)ethylidene]-5-(phenylmethyl)-24-pyrrolidinedione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nakamura M Kanda S Kawamura M et al. Effects of low concentration of vinblastine on the anchorage-independent growth and in vitro invasion of human renal carcinoma cell lines[J]. Cancer letters 1993 69(2):85-91.
molnova catalog
related products
-
cystine
Not considered one of the 20 amino acids, Cystine is a sulfur-containing derivative obtained from oxidation of cysteine amino acid thiol side chains.
-
Glycyrrhetinic acid
Enoxolone (INN, BAN; also known as glycyrrhetinic acid) is a pentacyclic triterpenoid derivative of the beta-amyrin type obtained from the hydrolysis of glycyrrhizic acid.
-
Calcium Levofolinate
Calcium Levofolinate, a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant.
